Trial Profile
A Global Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Designed Phase III Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and Older
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Tianjin CanSino Biotechnology
- 14 Jun 2023 Status changed from active, no longer recruiting to completed.
- 28 Oct 2022 Planned End Date changed from 30 Jan 2022 to 30 Nov 2022.
- 06 Jan 2022 Results published in the The Lancet